search icon
lpcn-img

Lipocine Inc, Common Stock

LPCN

NAQ

$4.37

-$0.08

(-1.8%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$23.37M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
42.03K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.19
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.2 L
$11.79 H
$4.37

About Lipocine Inc, Common Stock

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameLPCNSectorS&P500
1-Week Return-10.63%1.07%1.94%
1-Month Return-16.12%1.38%-2.02%
3-Month Return-13.29%-7.39%1.67%
6-Month Return-31.5%-6.25%6.34%
1-Year Return13.51%1.24%25.38%
3-Year Return-73.5%6.76%29.66%
5-Year Return-51.5%35.07%78.4%
10-Year Return-95.51%100.55%193.77%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue164.99K0.0416.14M500.00K(2.85M)[{"date":"2019-12-31","value":1.02,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.1,"profit":true},{"date":"2023-12-31","value":-17.66,"profit":false}]
Cost of Revenue7.47M9.75M7.67M8.56M10.18M[{"date":"2019-12-31","value":73.4,"profit":true},{"date":"2020-12-31","value":95.81,"profit":true},{"date":"2021-12-31","value":75.34,"profit":true},{"date":"2022-12-31","value":84.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(7.30M)(9.75M)16.14M500.00K(2.85M)[{"date":"2019-12-31","value":-45.25,"profit":false},{"date":"2020-12-31","value":-60.4,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.1,"profit":true},{"date":"2023-12-31","value":-17.66,"profit":false}]
Gross Margin(4426.46%)(24371172500.00%)100.00%100.00%100.00%[{"date":"2019-12-31","value":-4426.46,"profit":false},{"date":"2020-12-31","value":-24371172500,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses5.60M20.65M16.64M11.80M15.08M[{"date":"2019-12-31","value":27.1,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":80.56,"profit":true},{"date":"2022-12-31","value":57.15,"profit":true},{"date":"2023-12-31","value":73.01,"profit":true}]
Operating Income(12.90M)(18.00M)3.15M(12.12M)(17.93M)[{"date":"2019-12-31","value":-410.12,"profit":false},{"date":"2020-12-31","value":-572.13,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-385.29,"profit":false},{"date":"2023-12-31","value":-570.05,"profit":false}]
Total Non-Operating Income/Expense-(3.28M)(3.92M)1.91M2.94M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-111.38,"profit":false},{"date":"2021-12-31","value":-132.98,"profit":false},{"date":"2022-12-31","value":64.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(13.01M)(20.96M)(634.20K)(10.76M)(16.35M)[{"date":"2019-12-31","value":-1300714400,"profit":false},{"date":"2020-12-31","value":-2096461900,"profit":false},{"date":"2021-12-31","value":-63419900,"profit":false},{"date":"2022-12-31","value":-1075795500,"profit":false},{"date":"2023-12-31","value":-1635132700,"profit":false}]
Income Taxes200.00200.00200.00681.00755.00[{"date":"2019-12-31","value":26.49,"profit":true},{"date":"2020-12-31","value":26.49,"profit":true},{"date":"2021-12-31","value":26.49,"profit":true},{"date":"2022-12-31","value":90.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-(20.96M)(634.40K)(10.76M)(16.35M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2096481900,"profit":false},{"date":"2021-12-31","value":-63439900,"profit":false},{"date":"2022-12-31","value":-1075863600,"profit":false},{"date":"2023-12-31","value":-1635208200,"profit":false}]
Income From Continuous Operations(13.01M)(20.96M)(634.40K)(10.76M)(16.30M)[{"date":"2019-12-31","value":-1300734400,"profit":false},{"date":"2020-12-31","value":-2096481900,"profit":false},{"date":"2021-12-31","value":-63439900,"profit":false},{"date":"2022-12-31","value":-1075863600,"profit":false},{"date":"2023-12-31","value":-1629974200,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(13.01M)(20.96M)(634.40K)(10.76M)(16.35M)[{"date":"2019-12-31","value":-1300734400,"profit":false},{"date":"2020-12-31","value":-2096481900,"profit":false},{"date":"2021-12-31","value":-63439900,"profit":false},{"date":"2022-12-31","value":-1075863600,"profit":false},{"date":"2023-12-31","value":-1635208200,"profit":false}]
EPS (Diluted)(0.50)(0.40)0.05(0.13)(3.05)[{"date":"2019-12-31","value":-1000,"profit":false},{"date":"2020-12-31","value":-800,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-260,"profit":false},{"date":"2023-12-31","value":-6100,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LPCN
Cash Ratio 12.54
Current Ratio 12.97

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LPCN
ROA (LTM) -22.67%
ROE (LTM) -34.12%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LPCN
Debt Ratio Lower is generally better. Negative is bad. 0.08
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.92

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LPCN
Trailing PE NM
Forward PE NM
P/S (TTM) 4.96
P/B 1.24
Price/FCF NM
EV/R 0.50
EV/Ebitda 0.65
PEG NM

FAQs

What is Lipocine Inc share price today?

Lipocine Inc (LPCN) share price today is $4.37

Can Indians buy Lipocine Inc shares?

Yes, Indians can buy shares of Lipocine Inc (LPCN) on Vested. To buy Lipocine Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LPCN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Lipocine Inc be purchased?

Yes, you can purchase fractional shares of Lipocine Inc (LPCN) via the Vested app. You can start investing in Lipocine Inc (LPCN) with a minimum investment of $1.

How to invest in Lipocine Inc shares from India?

You can invest in shares of Lipocine Inc (LPCN) via Vested in three simple steps:

  • Click on Sign Up or Invest in LPCN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Lipocine Inc shares
What is Lipocine Inc 52-week high and low stock price?

The 52-week high price of Lipocine Inc (LPCN) is $11.79. The 52-week low price of Lipocine Inc (LPCN) is $3.2.

What is Lipocine Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Lipocine Inc (LPCN) is

What is Lipocine Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Lipocine Inc (LPCN) is 1.24

What is Lipocine Inc dividend yield?

The dividend yield of Lipocine Inc (LPCN) is 0.00%

What is the Market Cap of Lipocine Inc?

The market capitalization of Lipocine Inc (LPCN) is $23.37M

What is Lipocine Inc’s stock symbol?

The stock symbol (or ticker) of Lipocine Inc is LPCN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top